Publication | Closed Access
The cost-effectiveness of delayed-release dimethyl fumarate for the treatment of relapsing-remitting multiple sclerosis in Canada
30
Citations
41
References
2016
Year
Based on traditional cost-effectiveness thresholds in Canada (CAD $50 000-60 000), DMF can be considered a cost-effective option compared to other first-line DMTs.
| Year | Citations | |
|---|---|---|
Page 1
Page 1